Media
Hua Medicine appoints sales veteran Mr. Lu Yu as Vice President of Sales and Marketing Division
January 1, 2025 - China, Shanghai
Hua Medicine (the "Company", HKEx: 2552.HK) announced today that the Company appoints Mr. Lu Yu (陆宇) as Vice President of Sales and Marketing Division. Mr. Lu Yu has more than 20 years of experience in multinational pharmaceutical companies and nearly 20 years of experience in diabetes sales and marketing. He is familiar with key diabetes markets nationwide and has extensive experience in managing large-scale management teams.
Mr. Lu Yu will lead the newly established Sales and Marketing Division of Hua Medicine and will be fully responsible for the sales and promotion of the Company’s core product, HuaTangNing (华堂宁®) (dorzagliatin tablets), the world’s first innovative first-in-class glucokinase activator.
Prior to joining Hua Medicine, Mr. Lu Yu served as the senior director - national business at Eli Lilly China, managing a sales team of approximately 500 people. He was responsible for the sales and promotion of a full range of diabetes products in key markets nationwide, including insulin and GLP-1RA products. Previously, Mr. Lu Yu served as senior regional business director at Novo Nordisk, responsible for the sales and promotion of a full range of diabetes products.
Starting from January 1, 2025, Hua Medicine has upgraded its strategy and taken back the commercialization rights of HuaTangNing in China, and will continue to promote the national coverage of HuaTangNing through a self-built team. The first group of sales staff is already in place and actively conducting sales and promotion activity.
Dr. Li Chen, Founder and CEO of Hua Medicine, said: "We greatly welcome Mr. Lu Yu to join Hua Medicine's team, where he will lead and accelerate the market expansion of the Company's core product HuaTangNing. Mr. Lu Yu brings extensive experience and a proven track record in the field of diabetes product sales. We believe that he can lead Hua Medicine to accelerate the commercial promotion of innovative diabetes drugs and contribute to building a personalized platform for diabetes treatment in China. Hua Medicine will also continue to leverage its advantages in innovative drug research and development, enrich its drug development pipeline, and support the development of innovative drugs in China, aligning with Chinese characteristics and benefiting patients globally."
Mr. Lu Yu said: "It's my great honor to join Hua Medicine and work side by side with Dr. Li Chen and his team. As a leading company in the research and development of innovative drugs in China, Hua Medicine has successfully developed HuaTangNing. This is the world's first innovative drug, and it was successfully included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA) just one year after its launch, proving its great clinical application potential. Facing the unmet medical needs in the field of diabetes and the rapid growth of the Chinese pharmaceutical market, I look forward to working with Hua Medicine’s team to expand the brand awareness and market share of HuaTangNing in the next few years, achieve milestone sales and realize both economic and social value of innovative drugs."
About Hua Medicine
Hua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁®) (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁®) was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. At the end of 2023, HuaTangNing (华堂宁®) was successfully included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA), which was officially implemented on January 1, 2024.
For more information
Hua Medicine
Website: www.tj-zyix.com
Investors
E-mail: ir@tj-zyix.com
Media
E-mail: pr@tj-zyix.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
